We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




New Highly-Sensitive Test to Help More Easily Diagnose B-Cell Lymphoma

By LabMedica International staff writers
Posted on 05 Jul 2024
Print article
Image: The new test helps differentiate a B-cell cancer from a normal, reactive immune response (Photo courtesy of Roche)
Image: The new test helps differentiate a B-cell cancer from a normal, reactive immune response (Photo courtesy of Roche)

B-cell lymphoma, a cancer primarily originating in the lymphatic system, represents about 85% of non-Hodgkin lymphoma (NHL) diagnoses. NHL ranks as the tenth most prevalent cancer globally, claiming over 250,000 lives annually. In its early stages, NHL can manifest with symptoms such as swollen lymph nodes, fever, fatigue, loss of appetite, or a red rash. These symptoms, however, can mimic the body’s typical response to infections, making a precise diagnosis crucial. symptoms of lymphoma can appear similar to the body’s normal reactive response to an infection. Now, a first-of-its-kind assay can offer diagnostic certainty for patients with suspected B-cell lymphoma.

Roche (Basel, Switzerland) has introduced the first clinically approved, highly sensitive in-situ hybridization (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, available in regions accepting the CE Mark. This assay stands out as the first clinically approved ISH test designed to detect the entire range of B-cell lymphoma subtypes. It assists pathologists in distinguishing between a B-cell malignancy and a normal, reactive condition stemming from an infection.

This test’s enhanced sensitivity allows for the evaluation of over 60 different B-cell lymphoma subtypes and plasma cell neoplasms using just a single tissue slide. It is capable of analyzing small biopsies and formalin-fixed tissues, thus eliminating the necessity for fresh tissue samples, which might be unavailable, particularly when lymphoma was not initially suspected. The characteristics of this test not only conserve tissue but also potentially reduce the need for additional biopsies, simplify the diagnostic process for pathologists, and expedite both diagnosis and treatment access for patients.

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article
77 ELEKTRONIKA

Channels

Molecular Diagnostics

view channel
Image: A brain scan showing the presence of progressive supranuclear palsy in the area circled in red (Photo courtesy of UCSF)

Diagnostic Test Could Detect Elusive Neuro Disorder Using Tiny Drop of Spinal Fluid

Progressive supranuclear palsy (PSP) is a severe neurological disorder classified under frontotemporal dementia (FTD) that impairs cognition, movement, and behavior. Thought to be caused by an accumulation... Read more

Hematology

view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.